Gamida Cell Announces the Date of Its Third Quarter 2022 Financial Results and Webcast

Rhea-AI Summary

Gamida Cell (NASDAQ: GMDA) will host a conference call and live webcast on November 14, 2022, at 8:00 AM EST to discuss its Q3 2022 financial results and company updates. The call can be accessed via Gamida Cell's website, with a replay available for 30 days post-event. Gamida Cell focuses on developing NAM-enabled cell therapies for hematologic and solid cancers, including the investigational product omidubicel, which is under FDA review as a potential alternative for bone marrow transplants.

Positive

• Upcomig conference call to discuss Q3 2022 financial results can enhance investor transparency.
• Focus on NAM-enabled therapies could signify potential for innovative treatment solutions.

Negative

• No specific financial metrics or results provided, creating uncertainty.
• Dependence on regulatory approvals for product candidates adds risk.

BOSTON--(BUSINESS WIRE)-- Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced that the company will host a conference call and live audio webcast on Monday, November 14, 2022, at 8:00 AM EST to review its third quarter 2022 financial results and provide an update on the company.

To access the conference call, please register here and be advised to do so at least 10 minutes prior to joining the call. A live webcast of the conference call can be accessed in the “Investors & Media” section of Gamida Cell’s website at www.gamida-cell.com. A replay of the webcast will be available approximately two hours after the event, for approximately 30 days.

About Gamida Cell

Gamida Cell is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumor and blood cancers and other serious blood diseases. We apply a proprietary expansion platform leveraging the properties of NAM to allogeneic cell sources including umbilical cord blood-derived cells and NK cells to create therapy candidates with potential to redefine standards of care. These include omidubicel, an investigational product under review with the FDA as a potential life-saving alternative for patients in need of bone marrow transplant, and a line of modified and unmodified NAM-enabled NK cells targeted at solid tumor and hematological malignancies. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn, Twitter, Facebook or Instagram at @GamidaCellTx.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to timing of initiation and progress of, and data reported from, the clinical trials of Gamida Cell’s product candidates (including omidubicel and GDA-201), anticipated regulatory filings (including the timing of review of the BLA for omidubicel to the FDA), commercialization planning efforts, and the potentially life-saving or curative therapeutic and commercial potential of omidubicel, and Gamida Cell’s expectations for the expected clinical development milestones set forth herein. Any statement describing Gamida Cell’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to the impact that the COVID-19 pandemic could have on our business, and including the scope, progress and expansion of Gamida Cell’s clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; and those inherent in the process of developing and commercializing product candidates that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Gamida Cell’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (SEC) on August 15, 2022, and other filings that Gamida Cell makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and Gamida Cell’s actual results could differ materially and adversely from those anticipated or implied thereby. Although Gamida Cell’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Gamida Cell. As a result, you are cautioned not to rely on these forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221107005436/en/

For investors:

Courtney Turiano

Stern Investor Relations, Inc.

Courtney.Turiano@sternir.com

1-212-362-1200

For media:

Heather DiVecchia

Director, Investor Relations and Corporate Communications

Heather@gamida-cell.com

1-617-892-9083

Source: Gamida Cell Ltd.

FAQ

When will Gamida Cell announce its third quarter 2022 financial results?

Gamida Cell will announce its Q3 2022 financial results on November 14, 2022.

What is Gamida Cell's primary focus in its product development?

Gamida Cell focuses on NAM-enabled cell therapies for hematologic and solid cancers.

How can I access the conference call for Gamida Cell's financial results?

The conference call can be accessed through Gamida Cell's website; participants should register at least 10 minutes prior.

What is Omidubicel and its significance to Gamida Cell?

Omidubicel is an investigational product under FDA review as a potential life-saving alternative for patients needing bone marrow transplants.

What are the risks associated with Gamida Cell's product candidates?

Risks include dependence on regulatory approvals and the uncertainties inherent in clinical trials.